These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43 related articles for article (PubMed ID: 6238917)
21. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? : implications of resistance for acne patients and prescribers. Eady AE; Cove JH; Layton AM Am J Clin Dermatol; 2003; 4(12):813-31. PubMed ID: 14640775 [TBL] [Abstract][Full Text] [Related]
22. The use of oral antibiotics in treating acne vulgaris: a new approach. Farrah G; Tan E Dermatol Ther; 2016 Sep; 29(5):377-384. PubMed ID: 27306750 [TBL] [Abstract][Full Text] [Related]
24. The impact and importance of resistance. Tanghetti E Cutis; 2007 Jul; 80(1 Suppl):5-9. PubMed ID: 17824580 [TBL] [Abstract][Full Text] [Related]
25. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Leyden JJ; Del Rosso JQ; Webster GF Cutis; 2007 Jun; 79(6 Suppl):9-25. PubMed ID: 17649854 [TBL] [Abstract][Full Text] [Related]
26. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. Patel M; Bowe WP; Heughebaert C; Shalita AR J Drugs Dermatol; 2010 Jun; 9(6):655-64. PubMed ID: 20645527 [TBL] [Abstract][Full Text] [Related]
27. [Treating acne: avoid the development of antibiotic resistance by applying topical and combined therapy]. Abeck D MMW Fortschr Med; 2003 Dec; 145(51-52):29. PubMed ID: 14974325 [No Abstract] [Full Text] [Related]
28. Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects. Nord CE; Oprica C Anaerobe; 2006; 12(5-6):207-10. PubMed ID: 17000123 [No Abstract] [Full Text] [Related]
29. Recent advances in understanding Platsidaki E; Dessinioti C F1000Res; 2018; 7():. PubMed ID: 30613388 [TBL] [Abstract][Full Text] [Related]
30. [Effects of macrolide therapy on patients with acne vulgaris]. Akamatsu H Jpn J Antibiot; 2001 Feb; 54 Suppl A():109-12. PubMed ID: 11439886 [No Abstract] [Full Text] [Related]
31. Propionibacterium acnes, an emerging pathogen: from acne to implant-infections, from phylotype to resistance. Aubin GG; Portillo ME; Trampuz A; Corvec S Med Mal Infect; 2014 Jun; 44(6):241-50. PubMed ID: 24656842 [TBL] [Abstract][Full Text] [Related]
32. Gentamicin in ophthalmology. Records RE Surv Ophthalmol; 1976; 21(1):49-58. PubMed ID: 785654 [TBL] [Abstract][Full Text] [Related]
33. In vivo evaluation of antibacterial chemotherapeutic substances. Miller AK Adv Appl Microbiol; 1971; 14():151-83. PubMed ID: 4946253 [No Abstract] [Full Text] [Related]
35. The use of once-daily dosing of gentamicin in obstetrics and gynecology. Wiesenfeld HC; Heine RP Infect Dis Obstet Gynecol; 1998; 6(4):155-9. PubMed ID: 9812246 [TBL] [Abstract][Full Text] [Related]
36. The quinolones and dermatologic practice. Parish LC; Witkowski JA Int J Dermatol; 1986; 25(6):351-6. PubMed ID: 3531041 [No Abstract] [Full Text] [Related]
37. The effect of antibacterial agents on the flora of the skin. Ayliffe GA J Hosp Infect; 1980 Jun; 1(2):111-24. PubMed ID: 6182201 [No Abstract] [Full Text] [Related]
38. Antimicrobial therapy and resistance in dermatologic pathogens of the elderly. Hutchison LC Dermatol Clin; 2004 Jan; 22(1):63-71. PubMed ID: 15018010 [TBL] [Abstract][Full Text] [Related]
39. Antimicrobial properties of gentamicin on the skin. Lorenzetti OJ; Wernet TC; Breslauer CM Int J Dermatol; 1984 Oct; 23(8):547-9. PubMed ID: 6238917 [No Abstract] [Full Text] [Related]
40. Topical acne treatments in Europe and the issue of antimicrobial resistance. Leccia MT; Auffret N; Poli F; Claudel JP; Corvec S; Dreno B J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1485-92. PubMed ID: 25677763 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]